WILEY The current 60% five-year survival rate of individuals with oral squamous cell carcinoma (OSCC)—a type of cancer of the mouth and throat—could be greatly improved if treatments were initiated as early as possible. In a study published in Natural Sciences, researchers used a technology called conductive polymer spray ionization mass spectrometry to screen the blood...
Month: <span>June 2022</span>
Post
Fixing spinal cord injuries with ‘dancing molecules’
DOE/US DEPARTMENT OF ENERGY Image: In a new injectable therapy that repairs spinal cord injuries, molecules form nanofibers that ‘dance’ around, making communication with cells to repair the injured spinal cord more likely. Credit: Image courtesy of Northwestern University The Science A new injectable therapy for spinal cord injuries uses specially engineered molecules that trigger...
Post
Novel treatment for K-Ras mutant pancreatic tumors
CACTUS COMMUNICATIONS IMAGE: RESEARCHERS FROM CHINA HAVE DEVELOPED A NOVEL CONJUGATE THAT CAN SUPPRESS THE GROWTH OF K-RAS MUTANT PANCREATIC TUMORS WITH HIGH EFFICACY. CREDIT: JOURNAL OF PHARMACEUTICAL ANALYSIS Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. The K-Ras mutant pancreatic cancer is one of...
Post
Is monkeypox the next pandemic?
by Mary Cunningham, George Mason University Credit: Pixabay/CC0 Public Domain As more monkeypox infections are identified throughout the U.S. and the world, the public is more curious about the disease, especially because we are still in a global pandemic. Epidemiologist and professor at George Mason University Dr. Amira Roess answers more questions about monkeypox’s transmissibility,...
Post
Repurposing cancer drug to treat neuroinflammation
by Karolinska Institutet Graphical abstract. Credit: EMBO reports (2022). DOI: 10.15252/embr.202154499 The repurposing of FDA-approved drugs for alternative diseases is a faster way of bringing new treatments into the clinic. Researchers at Karolinska Institutet in Sweden have repurposed a cancer drug for treatment of neuroinflammatory diseases such as multiple sclerosis. A novel drug carrier was also developed...
Post
Genome-wide intricacies of cancer inhibitor untangled
by Will Doss, Northwestern University MYCi975 selectively affects MYC binding to promoters and target gene expression. (A) Heatmap representation of ChIP-seq signal at annotated promoters of MYCi975-sensitive sites (types 1, 2, and 3). (B) Log2(fold change) of genes for each type as calculated from differential gene expression analysis of DMSO- versus 48-hour MYCi975-treated 22Rv1 cells....
Post
This parasite will self-destruct: researchers discover new weapon against drug-resistant malaria
Diagrammatic representation of the target of the antimalarial compound ML901 (coloured structure), showing highly specific and potent inhibition of the malaria parasite. ML901 finds a particular chink in an enzyme called tyrosine tRNA synthetase (depicted in pink), part of the machinery that the malaria parasite uses to generate the proteins needed to reproduce itself. The...
Post
Improved survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant
by Dana-Farber Cancer Institute Credit: Pixabay/CC0 Public Domain Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option....
Post
Researchers: Breast cancer drug could help more patients
by Carla K. Johnson This undated photo provided by Daiichi Sankyo and AstraZeneca in June 2022 shows production of their Enhertu, an antibody-chemotherapy drug administered intravenously. Credit: Daiichi Sankyo, AstraZeneca via AP For the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very...
Post
Semaglutide 2.4 mg reduces CMDS score in patients with obesity
A late-breaking abstract was released today on a study in which patients were given a higher dose (2.4 mg) of semaglutide than is currently approved for weight management. Semaglutide, a GLP-1 analog drug approved at a higher dose (2mg) in March for type 2 diabetes, only received approval to treat obesity last year. In the STEP 1 trial, 1,961...